NuScale Stock Now Trades for About the Cash on Its Books. Should You Buy It Now?

NuScale closed at $4.37, about 92% below its October 2025 record, as Q3 revenue fell to $281,000 from $8.2 million a year earlier. The company ended September with about $1.86 billion in cash and investments, no debt, and a roughly $45.7 million quarterly net loss; it issued no shares in Q3. However, a binding TVA power agreement and subsequent module order could trigger nearly $1.2 billion and almost $1.7 billion in payments to ENTRA1, respectively, before NuScale sells modules, while no commercial agreement date has been provided.

Analysis

The key issue is not headline cash burn; it is whether the ENTRA1 milestone arrangement makes cash economically encumbered before NuScale receives module-sale proceeds. That creates an adverse sequencing risk: progress that validates the project may also trigger large partner payments, while a signed power deal still would not itself establish a NuScale order. Verify in the filing the payment dates, cash-versus-accounting treatment, refundability, and termination or offset rights before treating milestone estimates as certain cash outflows.

Near term, the sharp de-rating and still-slow burn argue against chasing a short solely on the cash-adjusted narrative; a binding TVA agreement could produce a relief rally even if its economics are unattractive to SMR shareholders. Over 1–3 months, the catalysts are clarified ENTRA1 terms, a binding power agreement, and evidence of an actual module contract. Over 6–18 months, manufacturing commitments, project financing, and potential use of the share-sale program determine dilution and execution risk. Competing nuclear designs and non-nuclear generation remain alternatives for TVA; a delay or scope reduction would weaken NuScale’s conversion case, while a real order could improve it.

Contrarian point: cash is not a reliable downside floor, but neither does a milestone-triggered payment automatically mean value destruction if it unlocks bankable, funded orders. The decisive evidence is cash paid versus contracted customer receipts—not project announcements.

Key Decisions for Investors

• Do not underwrite SMR as a cash-backed value trade until the ENTRA1 agreement’s payment mechanics and remaining obligations are reconciled to cash and commitments in the filing.
• Avoid chasing an outright short after the large drawdown. If taking a bearish view, consider a defined-risk put spread only after checking implied volatility and liquidity; the thesis is falsified by a funded module order with disclosed customer receipts that materially cover milestone payments.
• Put SMR on a catalyst watch: require binding TVA/ENTRA1 terms, module-sale documentation, and updated cash-flow guidance before adding. Track ATM issuance and manufacturer spending; rising share count or cash use without signed orders would strengthen the downside case.